Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
A phase 1/2 trial of Alemtuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Cellectis S.A., now recruiting.
Overview
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05607420 by Cellectis S.A., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-08. Interventions recorded: UCART20x22, CLLS52. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.
Setting
Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
Phase
Phase 1/2
Sponsor
Cellectis S.A.
Registry
Enrolled
80
Similar pages
not linked directly; found by shared links- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- TrialA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat
- TrialSafety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- TrialA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom
- TrialCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma